{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-09-01T05:29:07.659565+00:00","company":{"ticker":"CNTB","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd"},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"the purchasers named therein","detail":"equity_purchase","count":1,"first_seen":"2026-03-30T23:59:59+00:00","last_seen":"2026-03-30T23:59:59+00:00","evidence_fact_ids":[26644]}]},"facts":[{"fact_type":"earnings_release","fact_key":"9e1ec4fa4b62e3cc4660dac94512251fea599b55","cik":1835268,"ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-05-12T13:02:24+00:00","payload":{"eps_text":"($0.34) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$19.4 million","period_text":"the three months ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":"$0.2 million"},"claim":"Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.","evidence_excerpt":"its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001835268-26-000019","anchor_url":"https://secwatch.observer/filing/0001835268-26-000019#claim-9e1ec4fa4b62e3cc4660dac94512251fea599b55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm"},{"fact_type":"earnings_release","fact_key":"d4c3c398914f3b1c00daf31ee1b277170be8def2","cik":1835268,"ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-03-31T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the three and twelve months ended December 31, 2025","report_date":"2026-03-31","result_type":"reported_results","revenue_text":null},"claim":"Connect Biopharma Holdings Ltd reported financial results for the three and twelve months ended December 31, 2025.","evidence_excerpt":"On March 31, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001835268-26-000012","anchor_url":"https://secwatch.observer/filing/0001835268-26-000012#claim-d4c3c398914f3b1c00daf31ee1b277170be8def2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/0001835268-26-000012-index.htm"},{"fact_type":"equity_issuance","fact_key":"5bd9dcc2e7f482971cb9d68e44514e29d51c3518","cik":1835268,"ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$3.25 per Share","effective_date":"2026-03-29","item_codes_triggered":["3.02"],"purchaser":"institutional accredited investors","security_type":"common_stock","shares_text":"6,130,000 shares"},"claim":"Connect Biopharma Holdings Ltd issued 6,130,000 shares of common stock to institutional accredited investors for $3.25 per Share.","evidence_excerpt":"On March 29, 2026, Connect Biopharma Holdings Limited (the \"Company\") entered into a securities purchase agreement (the \"Purchase Agreement\") with the purchasers named therein (the \"Purchasers\"), for the private placement (the \"Private Placement\") of 6,130,000 shares (the \"Shares\") of the Company's ordinary shares, par value $0.000174 per share (the \"Ordinary Shares\"), at a price of $3.25 per Share with respect to any Purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001835268-26-000006","anchor_url":"https://secwatch.observer/filing/0001835268-26-000006#claim-5bd9dcc2e7f482971cb9d68e44514e29d51c3518","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm"},{"fact_type":"material_agreement","fact_key":"3fe3319bacb63072c70c55ffabcf637e3ae37a35","cik":1835268,"ticker":"CNTB","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-03-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"the purchasers named therein","effective_date":"2026-03-29","item_codes_triggered":["1.01"],"value_text":"approximately $20.2 million"},"claim":"Connect Biopharma Holdings Ltd entered into Purchase Agreement with the purchasers named therein valued at approximately $20.2 million (effective 2026-03-29).","evidence_excerpt":"On March 29, 2026, Connect Biopharma Holdings Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 6,130,000 shares (the “Shares”) of the Company’s ordinary shares, par value $0.000174 per share (the “Ordinary Shares”), at a price of $3.25 per Share","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001835268-26-000006","anchor_url":"https://secwatch.observer/filing/0001835268-26-000006#claim-3fe3319bacb63072c70c55ffabcf637e3ae37a35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/0001835268-26-000006-index.htm"}]}